Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/15/2018 05/16/2018 05/17/2018 05/18/2018 05/21/2018 Date
121.55(c) 121(c) 121.15(c) 121.07(c) 119.37(c) Last
1 649 314 1 031 290 755 982 1 098 803 1 187 668 Volume
-1.06% -0.45% +0.12% -0.07% -1.40% Change
More quotes
Financials (USD)
Sales 2018 4 000 M
EBIT 2018 1 954 M
Net income 2018 480 M
Debt 2018 1 400 M
Yield 2018 -
Sales 2019 4 673 M
EBIT 2019 2 349 M
Net income 2019 1 372 M
Finance 2019 3 159 M
Yield 2019 -
P/E ratio 2018 49,44
P/E ratio 2019 19,35
EV / Sales2018 7,09x
EV / Sales2019 5,09x
Capitalization 26 956 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
07/26Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
05/15ALEXION PHARMACEUTICALS : to Present at the Bank of America Merrill Lynch 2018 H..
AQ
05/11ALEXION PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holder..
AQ
05/08ALEXION PHARMACEUTICALS : to Present at the Bank of America Merrill Lynch 2018 H..
BU
04/30Ex-Synageva team planning Kiniksa IPO
AQ
04/26ALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
04/26ALEXION PHARMACEUTICALS : Alexion Pharmaceuticals, Inc. to Host Earnings Call
AC
04/26ALEXION PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
AQ
04/26ALEXION : 1Q Earnings Snapshot
AQ
04/26ALEXION PHARMACEUTICALS : Reports First Quarter 2018 Results and Positive Toplin..
BU
04/26ALEXION PHARMACEUTICALS : Shares Rise After Guidance Lift, Study Results
DJ
More news
Sector news : Biopharmaceuticals
05/21MERCK AND : Ebola Vaccination Begins in Democratic Republic of Congo -- Update
DJ
05/21MERCK AND : Factbox - From sterling crises to Brexit, the tests of Bank of Engla..
RE
05/21ASTRAZENECA : potassium drug finally approved, threatening Vifor
RE
05/21EU Approves GlaxoSmithKline JV's Juluca HIV Treatment
DJ
05/21MERCK AND : Ebola Vaccine Arrives in Democratic Republic of Congo
DJ
More sector news : Biopharmaceuticals
Latest Tweets
05/18Alexion Pharmaceuticals $ALXN – Investment Analysts’ Recent Ratings Changes  
05/16$ALXN Event Reminder for Alexion Pharmaceuticals, Inc. From our Stock News Al.. 
05/16Zacks: Brokerages Expect Alexion Pharmaceuticals $ALXN to Announce $1.68 Earn.. 
05/16Alexion publishes a supplement to the offer document regarding its recommende.. 
05/16Confident Investor indicator analysis for 5/16/2018. Interesting results from.. 
More tweets
Qtime:130
News from SeekingAlpha
05/14JF'S CORE BIOTECH BUYS #15 : Removal Of A Key Overhang, Buying Weakness In I-O, .. 
05/10INSTITUTIONAL TOP IDEAS SERIES : Ra Capital Management 
05/07JF'S CORE BIOTECH BUYS #14 : Introducing Our Final 2 Positions & Taking Advantag.. 
05/05DAILY INSIDER RATINGS ROUND UP 5/2/1 : Sohu, bw, ddr, nhf, abcp, alxn 
05/04INSTITUTIONAL TOP IDEAS SERIES : Orbimed Advisors 
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 159 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS1.24%26 956
CSL LIMITED29.48%62 149
BIOGEN-11.98%59 202
GRIFOLS3.05%18 482
BIOMARIN PHARMACEUTICAL-0.85%15 627
WUXI BIOLOGICS CAYMAN INC--.--%12 447